Article Text

Download PDFPDF
High-sensitivity troponin: elevated without infarction, is the horse out of the barn?
  1. Sanjiv Baxi1,
  2. Joshua Lakin1,
  3. Sahael Stapleton1,
  4. Rita Redberg1,2
  1. 1Department of Medicine, University of California San Francisco, San Francisco, California, USA
  2. 2Division of Cardiology, University of California San Francisco, San Francisco, California, USA
  1. Correspondence to Dr Sanjiv Baxi, Department of Medicine, University of California San Francisco Medical Center, 513 Parnassus Avenue, Med Science, Room S380, San Francisco, CA 94143, USA; sanjiv.baxi{at}ucsf.edu

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Ischaemic heart disease persists as the world's leading cause of mortality with serious consequences for unrecognised disease.1 Chest pain, the cardinal symptom of acute coronary syndromes (ACS), accounts for over six million adult emergency department (ED) visits in the USA and greater than 360 000 in England and Wales each year.2 ,3 If ACS is diagnosed early, there are effective interventions that improve outcomes. Therefore, increasing our diagnostic accuracy in ACS, specifically for acute myocardial infarctions (AMI), including both ST segment and non-ST segment elevation, is critical. A major part of these efforts is the use of biomarkers, primarily the serum troponin assay. To address the expanding clinical use of different troponin assays, the American College of Cardiology Foundation (ACCF) recently issued guidelines on interpreting troponin assays in the clinical setting.4 It notes several recent studies supporting high-sensitivity troponin (HS-Tn) assays as a mechanism to rapidly rule out AMI. These assays are quickly replacing troponin-I as the standard of care in routine clinical practice.4–8 However, these studies do not address one consequence of increasing sensitivity: the tradeoff of increased positive results in the absence of ACS and their associated patient health and financial costs.

Several studies have demonstrated the ability of HS-Tn assays to rapidly ‘rule out’ AMI in their respective populations when coupled with standard clinical assessment and ECG.4–8 Achieving a ‘rapid rule-out,’ that is, quickly obtaining accurate negative results, is helpful for the process of safely excluding persons without AMI. A perfect test would achieve …

View Full Text

Footnotes

  • Contributors SMB was directly involved in planning (generating the concept, organising the work flow, manuscript review), conduct (generating the manuscript) and reporting of the manuscript (statistical analysis, manuscript submission). He served as the overall content guarantor. JL was directly involved in planning (generating the concept, organising the work flow, manuscript review), conduct (generating the manuscript) and reporting of the manuscript. SS was directly involved in planning (generating the concept, organising the work flow, manuscript review), conduct (generating the manuscript) and reporting of the manuscript (statistical analysis). RR was directly involved in planning (manuscript review), conduct (generating the manuscript) and reporting of the manuscript (analytic review), as well as serving in a mentorship capacity.

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.